

Review

Open Access

Moxidectin: a review of chemistry, pharmacokinetics and use in horses

Rami Cobb and Albert Boeckh*

Address: Fort Dodge Animal Health, Pharmaceutical Research and Development, Princeton, NJ, USA

Emails: Rami Cobb - cobbr@pt.fdah.com; Albert Boeckh* - boeckha@pt.fdah.com

*Corresponding author

Published: 25 September 2009

Parasites & Vectors 2009, **2**(Suppl 2):S5 doi:10.1186/1756-3305-2-S2-S5

This article is available from: <http://www.parasitesandvectors.com/content/2/S2/S5>

© 2009 Cobb and Boeckh; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

This article reviews the current knowledge of the use of moxidectin (MOX) in horses, including its mode of action, pharmacokinetic and pharmacodynamic properties, efficacy, safety and resistance profile.

Moxidectin is a second generation macrocyclic lactone (ML) with potent endectocide activity. It is used for parasite control in horses in an oral gel formulation. The principal mode of action of MOX and of other MLs is binding to gamma-aminobutyric (GABA) and glutamate-gated chloride channels. Moxidectin is different from other MLs in that it is a poor substrate for P-glycoproteins (P-gps) and therefore less susceptible to elimination from parasite cells through this mechanism. Due to its unique physico-chemical and pharmacokinetic characteristics, MOX provides broad distribution into tissues, long half-life, significant residual antiparasitic activity, and high efficacy against encysted cyathostomin larvae. These characteristics allow for high efficacy and longer treatment interval against all important nematodes, when compared to other equine anthelmintics. A combination of MOX with praziquantel provides expanded spectrum of activity by adding activity against cestodes. Appropriate use of MOX allows for the development of strategic anthelmintic programmes that are different from those with conventional anthelmintics. Fewer treatments are required over a period of time, and therefore impose less frequent selection pressure for resistance.

Introduction

Moxidectin is a potent, broad-spectrum endectocide with activity against a wide range of nematodes, insects and acari. It is used worldwide as a parasiticide in a variety of mammalian species including food-producing and companion animals.

The first MOX-containing product was an injectable formulation for cattle, approved for commercial use in

Argentina in 1989. Subsequent formulations introduced worldwide for control of parasitosis include a tablet and a sustained release injectable for prevention of heartworm disease in dogs, injectable and oral drenches for sheep, a pour-on formulation for cattle and deer, and sustained release injectable formulations for cattle and sheep. These long-acting formulations provided significantly longer persistent activity than the earlier formulations, including season-long control against some parasite species.

Combination products, including an injectable formulation of MOX with clostridial and caseous lymphadenitis vaccines for sheep, are commercially available in major sheep producing countries. Additionally, an ongoing collaboration between Wyeth/Fort Dodge Animal Health and the World Health Organization led to the development of an oral formulation of MOX for humans, which is being evaluated in several African countries for prevention of river blindness, a parasitic disease caused by *Onchocerca volvulus*.

For horses, MOX is formulated as unique, easy-to-administer oral gel formulation that provides excellent and long-lasting efficacy against nematodes and gastrointestinal bots. A second gel formulation containing MOX in combination with praziquantel adds efficacy against cestodes.

Chemistry and pharmacology

Moxidectin is a semi-synthetic methoxime derivative of LL F-2924 α , commonly referred as F-alpha or nemadectin, a 16-member pentacyclic lactone of the milbemycin class. F-alpha is a product of fermentation of *Streptomyces cyaneogriseus* subsp. *noncyanogenus*, a bacterial organism isolated in 1983 from a sample of sand from Victoria, Australia. F-alpha possesses strong anthelmintic activity but has limited ectoparasiticide activity. Moxidectin is the result of chemical optimization of F-alpha. Moxidectin differs from ivermectin (IVM) by the absence of a disaccharide moiety on carbon-13, a substituted olefinic side chain at carbon 25 and a unique methoxime moiety at carbon-23. Due to differences in chemistry and biological activity compared to other MLs developed for similar uses, MOX is classified as a second generation ML.

Studies to determine the mode of action of MLs on parasites demonstrated that these compounds act by binding to ligand-gated chloride channels, more specifically the subtypes that are gamma-aminobutyric (GABA-A) mediated and glutamate-gated [1]. The consequence of ML binding and activation is an increased permeability, leading to an influx of chloride ions and flaccid paralysis of the parasite leading to death. Recent work identified a dopamine-gated ion channel (HcGGR3) in *Haemonchus contortus* that is associated with ML resistance [2].

A number of differences in the modes of action of avermectins and milbemycins have been proposed for ruminant parasites. One example is the difference in the degree of pharyngeal pumping activity present in *Haemonchus contortus* that has undergone selection with IVM. In this selected strain of *H. contortus*, pharyngeal pumping activity is altered in presence of IVM, but unchanged in the presence of MOX, suggesting to some extent a difference in mode of action [3]. Another

example is the degree of transport of MLs by p-glycoproteins (P-gp). P-gps are transmembrane pumps that have been shown to reduce the uptake of lipophilic compounds from the GI tract, to limit penetration into tissues, including brain, and to enhance elimination by biliary, intestinal or renal secretion. MOX is a poor substrate for P-gps, compared to other MLs, such as IVM and selamectin. This is demonstrated by the significantly lower rate ($p < 0.01$) of transport of radiolabeled MOX, compared to radiolabeled IVM and selamectin, across human intestinal epithelial cell monolayers and canine peripheral lymphocyte membrane both from basal to apical direction as well as from apical to basal direction [4].

The toxicity of MLs is believed to be dependent, in part, on transport by P-gps [4,5]. P-glycoproteins act as transport proteins able to carry certain drugs, including MLs, across cell membranes. Over- or under-expression of P-gps can lead to accumulation or depletion of a compound within cells.

In the case of over-accumulation in cells of the nervous system, signs of neurotoxicity may be seen, even when the recommended commercial dose has been administered. Investigations into the sensitivity of some collie-type dogs to IVM have identified the presence of genetically based P-gp deficiency which leads to neurotoxicity at doses considered safe in the broader canine population. Comparisons of the affinity of MLs for P-gps demonstrated that MOX is a poor substrate for P-gps and differs in this property by an order of magnitude from the avermectins, such as IVM. This may explain the greater mammalian safety of MOX compared to IVM, most notably in P-gp deficient animals, such as some collie dogs [6-8]. This property of MOX means the benefits of monthly, or longer sustained release protection against heartworm infection is available for dogs susceptible to toxicity from IVM-based products [9].

The converse of P-gp deficiency, namely P-gp over-expression, is increasingly identified as being an important factor in anthelmintic resistance in nematodes. A clinical conundrum for many years has been why MOX is effective in controlling IVM-resistant nematodes when both are classified as MLs. The differing affinity for P-gps of MOX in comparison with the avermectins may play an important role. Selection on a P-gp gene has been identified in ML-selected nematode strains [10]. However, quantitative and qualitative differences have been identified between MOX and IVM in this selection. Further studies of the P-gps lend additional support to the importance of these transport proteins in the development of resistance to MLs [11,12].

The disposition of MOX in horses is well described, including its metabolic fate. Studies conducted with the

use of radiolabeled MOX formulated as an oral gel demonstrated that fecal excretion of the parent compound was the main elimination pathway, accounting for 77% of the dose administered [13], thus confirming that the product remains predominantly as the active parent compound and is not extensively broken down to less active metabolites.

Comparative pharmacokinetics of MOX and IVM after oral administration to horses were also performed [14]. Horses were treated orally with a gel formulation at the label dose of 0.4 mg of MOX per kg of body weight. Blood was collected over time and plasma assayed by high performance liquid chromatography with fluorescence detection. Results showed MOX has a favorable pharmacokinetic profile compared to IVM, including a longer elimination half-life and greater area under the curve. These are summarized in Table 1. The longer time course of MOX in horses leads to a longer exposure of parasites to MOX. This delivers a positive impact on efficacy as demonstrated by the longer egg reappearance interval following treatment and the high efficacy against stages of parasites not readily controlled by other compounds. In addition to plasma pharmacokinetics, another study documented the residue profile of MOX in selected horse tissues after oral administration of the commercial gel formulation at the label dose [15]. Concentrations of MOX in tissues are summarized in Table 2. As expected, due to its lipid solubility, MOX was found at highest levels in the abdominal and subcutaneous fat. This fat depot naturally releases MOX into the systemic circulation over time and contributes to the long half-life and sustained activity. Conversely, little MOX was found in lean tissues, such as muscle, supporting a short withholding period for meat. This is consistent with tissue residue data from cattle [16] and sheep [17] confirming a consistent metabolic and residue profile for MOX in major domestic species.

Efficacy and safety

The efficacy of MOX for nematode control in horses is well documented in controlled laboratory studies, field efficacy studies and by years of use by veterinarians and horse owners around the world. Typical study results are reported by Cleale et al. in a multicenter evaluation of pastured horses in 3 states of the United States, where 72 pastured horses were studied in Idaho, Illinois and Tennessee [18]. Animals had an average age of 32, 32 and 18 months in Idaho, Illinois and Tennessee, respectively and average pre-treatment fecal egg counts (EPG) of 266 (range 78-392), 108 (range 31-1042) and 576 (range 10-2850) eggs in the same States. The horses were randomly divided into 2 groups, one treated with MOX gel at the label dose of 0.4 mg/kg orally and the other group left as untreated control. Parasitocidal efficacy was determined

Table 1 - Comparative pharmacokinetics of moxidectin (MOX) and ivermectin (IVM) after oral administration in horses expressed as mean (\pm SD)

| | IVM | MOX |
|---------------------------|---------------------|---------------------|
| Dose (mg/kg) | 0.2 | 0.4 |
| Cmax (μ g/mL) | 44.0 (\pm 23.1) | 70.4 (\pm 10.7) |
| Tmax (day) | 0.38 (\pm 0.24) | 0.37 (\pm 0.19) |
| T1/2 elim (day) | 4.25 (\pm 0.29) | 23.11 (\pm 11.0) |
| AUC 0-t (μ g/day/mL) | 132.7 (\pm 47.3) | 363.6 (\pm 66.0) |

Cmax = Maximum concentration

Tmax = Time for maximum concentration

T1/2 = Terminal half-life

AUC = Area Under the concentration vs. time Curve

Table 2 - Tissue concentrations of moxidectin (MOX) after oral administration of 0.4 mg/kg to horses.

| Tissue | Concentration of MOX (ppb) |
|---------------|----------------------------|
| Abdominal fat | 884 |
| Back fat | 664 |
| Liver | 184 |
| Kidney | 51 |
| Muscle | 21 |

ppb = parts per billion

by necropsy and parasite count, conducted 12 to 14 days after treatment. Horses were determined to have a mixed infection of ascarids, small strongyles, large strongyles, tapeworms and bots. As expected, no efficacy of MOX was observed against the tapeworm *Anoplocephala perfoliata*. For all other parasites encountered, including *Gasterophilus* spp. larvae, adult and larval stages of ascarids and large and small strongyles, efficacy was greater than 95%, representing a significant difference from control ($p < 0.05$) as demonstrated in Tables 3 and 4, which contains pooled data from all 3 geographical locations.

Other efficacy studies have demonstrated differences in results following the treatment of cyathostomes by either MOX or IVM. One such study was conducted on six horse farms in Northwest Arkansas [19]. A total of 96 horses that were scheduled for anthelmintic treatment were randomly divided into 3 groups and treated with either MOX (QUEST – Fort Dodge Animal Health, Overland Park, KS, USA), IVM (EQVALAN – Merial Limited, Duluth, GA, USA) or fenbendazole (FBZ) (PANACUR – Intervet/Shering-Plough, Millsboro, DE, USA), according to label directions. Evaluation of efficacy was performed by fecal egg count tests comparing counts prior to treatment, on Day 0, with FECs conducted on Days 56, 84 and 112 after treatment. On Day 0, FECs did not vary across treatment groups, but significant differences were seen across treatment groups on the post-treatment evaluations, with superior efficacy of MOX, followed IVM and FBZ ($p < 0.05$), as demonstrated in Table 5. The results

Table 3 - Geometric means of egg counts and percent efficacy of moxidectin (MOX) against non-cyathostomins, compared to control

| | Geometric means | | |
|--|-----------------|-------|------------------|
| | control | MOX | Percent Efficacy |
| <i>Anoplocephala perfoliata</i> | 4.56 | 2.58 | 43.3 |
| <i>Gasterophilus intestinalis</i> 2nd instar | 16.19 | 0.66* | 95.5 |
| <i>Gasterophilus intestinalis</i> 3rd instar | 68.1 | 2.75* | 96.0 |
| <i>Gasterophilus nasalis</i> 2nd instar | 2.24 | 0.00* | 100.0 |
| <i>Gasterophilus nasalis</i> 3rd instar | 5.27 | 0.02* | 99.6 |
| <i>Oxyuris equi</i> L4 | 8.39 | 0.31* | 96.3 |
| <i>Parascaris equorum</i> adult | 1.78 | 0.07* | 96.3 |
| <i>Parascaris equorum</i> L4 | 1.02 | 0.00* | 100.0 |
| <i>Strongylus edentatus</i> adults | 2.41 | 0.03* | 98.7 |
| <i>Strongylus vulgaris</i> adults | 5.27 | 0.21* | 96.1 |
| <i>Triodontophorus brevicaudata</i> adults | 9.49 | 0.00* | 100.0 |
| <i>Triodontophorus serratus</i> adults | 22.04 | 0.00* | 100.0 |

* significant difference from control (p<0.05)

Table 4 - Geometric means of egg counts and percent efficacy of moxidectin (MOX) against cyathostomins, compared to control

| | Geometric means | | |
|--------------------------------------|-----------------|--------|------------------|
| | Control | MOX | Percent Efficacy |
| <i>Coronocyclus coronatus</i> | 205.06 | 0.07* | 99.97 |
| <i>Coronocyclus labiatus</i> | 126.98 | 0.00* | 100 |
| <i>Coronocyclus labratus</i> | 403.12 | 0.09* | 99.98 |
| <i>Cyathostomum catinatum</i> | 3917.4 | 0.00* | 100 |
| <i>Cyathostomum pateratum</i> | 128.89 | 0.00* | 100 |
| <i>Cylicocyclus brevicapsulatus</i> | 9.41 | 0.00* | 100 |
| <i>Cylicocyclus elongatus</i> | 8.59 | 0.00* | 100 |
| <i>Cylicocyclus insigne</i> | 134.65 | 0.18* | 99.86 |
| <i>Cylicocyclus leptostomum</i> | 935.71 | 0.00* | 100 |
| <i>Cylicocyclus nassatus</i> | 5073.92 | 0.09* | >99.99 |
| <i>Cylicocyclus radiatus</i> | 46.45 | 0.09* | 99.81 |
| <i>Cylicostephanus calicatus</i> | 1080.56 | 0.09* | 99.99 |
| <i>Cylicostephanus goldi</i> | 113.53 | 0.00* | 100 |
| <i>Cylicostephanus longibursatus</i> | 7518.56 | 0.09* | >99.99 |
| <i>Cylicostephanus minutus</i> | 5585.9 | 0.66* | 99.99 |
| <i>Petrovinema poculatus</i> | 18.89 | 0.00* | 100 |
| <i>Poteriostomum imparidentatum</i> | 3.69 | 0.00* | 100 |
| Luminal cyathostominL4 | 3726.11 | 21.60* | 99.42 |

* significant difference from control (p<0.05)

of this study have great significance in the development of strategic anthelmintic dosing programmes in that they not only confirm the high efficacy of MOX against key equine parasites, but also show that less frequent anthelmintic treatments are needed if MOX is used for cyathostome control.

While MOX may be used interchangeably with other effective anthelmintics for broad spectrum control of nematodes, it also has the potential to be used differently by applying its known characteristics of high potency and long duration of activity. Sustainable worm control programmes can be designed that provide the same level

Table 5 - Percent reduction in nematode egg count after treatment on Day 0

| | Days after treatment | | |
|--------------|----------------------|-------|-------|
| | 56 | 84 | 112 |
| Moxidectin | 99.1 | 97.6 | 94.9 |
| Ivermectin | 85.9 | 24.2 | -8.1 |
| Fenbendazole | 16.4 | -27.0 | -32.0 |

of protection from worms through fewer treatments, thus reducing the selection pressure for resistance.

One of the significant differentiating factors of MOX from other MLs is the efficacy against encysted stages of cyathostomes, the causal agents of larval cyathostominosis. This clinical syndrome is characterized by the simultaneous emergence of larvae leading to significant inflammatory enteropathy in the cecum and colon, and resulting in colitis, weight loss, diarrhea and colic. The high efficacy of MOX against inhibited stages of cyathostomins is well documented in the published literature [20-22]. A dilemma for clinicians in managing control of cyathostomin infections is whether treatment with an anthelmintic effective against luminal and developing stages only, will trigger mass emergence of inhibited stages with the associated clinical syndrome, or whether treatment using larvicidal products will lead to a mass die off of inhibited stages that may cause inflammatory responses in the mucosa and colic. A recently published study described the evaluation of the degree of inflammation caused by the killing of encysted cyathostomins larvae using either MOX or FBZ [23]. In that study, MOX was administered orally once at 0.4 mg/kg, while FBZ was administered daily for 5 days at the dose of 7.5 mg/kg. Animals were then sacrificed and parasites recovered 14 days after treatment. While both compounds were effective in removing larval cyathostomins, indicating a strain that is susceptible to both compounds, there was a significant difference in the degree of mucosal inflammation associated with the larval kill. Histologically, in animals treated with FBZ, T-lymphocytes accumulated around the intact larvae forming a granuloma along with eosinophils, with the inflammation extending into the mucosa and being associated with ulcerations. Conversely, in horses treated with MOX, morphological alterations were not observed in histopathology, and the disintegrated larvae resorbed without causing severe inflammation in the gut wall. Based on the safety and efficacy profile demonstrated for MOX, the clinician has available the means to control all stages of cyathostomins without the necessity to adjust from a normal dose or to administer repeated treatments, and without inducing severe inflammatory responses.

The use of MOX in pregnant mares was demonstrated to be safe in studies conducted during the registration phase of the gel formulation [24]. In addition a study was conducted to explore the impact of a strategic MOX treatment of perinatal mares on worm control in their foals [25]. In that study, a group of 25 pregnant mares was divided into 2 groups with 12 being treated with MOX oral gel at the label dose around the time of foaling, and 13 were left as untreated controls. Foals were born from Day -1 to Day 76. Based on coproculture and pasture analysis, the nematode challenge was predominantly of *Cyathostomum* spp. Complete control of parasites, including *Strongyloides westeri*, was maintained for at least 91 days in the mares and in the foals born from mares that were treated with MOX. In this study, the parasite challenge in the mares was significant, and the control mares had to be treated with IVM on grounds of welfare. At the end of the grazing period, the foals born from mares treated with MOX had an average body weight 17 kg higher than those born from mares that were treated with IVM (control mares) despite the fact that their foals were themselves treated with IVM at the age of 3 months. The potential of using MOX in perinatal mares to control nematode infections in foals warrants further investigation.

The potential of tapeworms to induce colic in horses has been documented [26-28] and combining MOX with the potent cestocide praziquantel allows simultaneous treatment of roundworms and tapeworms in a single application. The efficacy and safety of this combination product was demonstrated in a large field evaluation where four hundred client-owned horses were treated with either the combination of MOX + praziquantel or control. In that study, no adverse event was observed and a reduction of over 99% of *Anoplocephala* spp. and over 98% reduction in strongyle egg counts was observed [29]. Other less prevalent tapeworms, such as *Anoplocephala magna* and *Paranoplocephala mamillana*, are also known to have clinical significance in the horse [30]. Efficacy studies conducted on horses naturally infected with cestodes that were divided into matching treated and untreated groups demonstrated, at necropsy, the complete efficacy of the combination of MOX plus praziquantel against these tapeworms [31].

Another differentiating feature of MOX compared to other MLs is the environmental profile, most notably the low impact of MOX residues in faeces on the emergence rate of dung beetles in contrast to the findings with avermectins [32]. This was demonstrated in evaluation of the rate of emergence of the dung beetle *Aphodius constans* exposed to feces of horses treated orally with the combination of MOX and praziquantel [33]. Dung beetles play an important role in parasite control by

providing rapid dispersal and/or burial of dung and therefore reducing the habitat for nematode eggs and larvae, in addition to providing improvement in pasture.

Concerns about the potential development of resistance to MLs have been debated in the equine parasitology community for some years [34,35]. Increasing concerns have arisen with recent reports of the inefficacy of MLs, both IVM and MOX against *Parascaris equorum*. Such failures were reported initially from the Netherlands [36], later from North America [37-39], then other European countries [40-42] and most recently Brazil [43]. Frequency of anthelmintic treatments has been cited as a major contributing factor for selection for resistance by many parasitologists, and a review of common nematode control practices in horses indicates the highest frequency of treatments is in foals, specifically for the control of ascarids. Hence, the appearance of resistance under these conditions is not surprising, also taking into account that the initial efficacies of MLs against *P. equorum* indicated this was a dose-limiting species for this group of compounds. The reduced efficacy of anthelmintics in young versus adult horses has been long recognized [44]. Further concerns on the development of ML resistance are related to the reported reduction in the egg reappearance period (ERP) of cyathostomins following IVM treatment [45]. This is taken as a first sign of reduced sensitivity of cyathostomins to IVM.

The complexity of the mechanisms of resistance to MLs and our incomplete understanding of them has led to varied and different proposals for the best way of minimizing selection for resistance and preserving the efficacy of MLs for as long as possible. Factors to consider include optimal treatment frequency; should the less potent compound, IVM, be used until it is ineffective, then MOX used to control these parasites; what role as "refugia" is played by inhibited stages that are not effectively controlled by IVM, but against which MOX has high potency; and is there a link between benzimidazole resistance and ML resistance as selection has been shown at the beta-tubulin site for both classes of compounds [46].

One aspect on which there is general agreement is that anthelmintic treatments should be used only when needed, and recommendations have been made to monitor faecal egg counts and treat individual horses only when needed. A consensus on the appropriate threshold for treatment has not been reached but is of the order of 150-200 eggs per gram. The extended egg reappearance interval for MOX means the same level of control can be obtained with fewer treatments than with IVM [47-49]. The issue of the impact of treating inhibited cyathostomes has led to heated debate. The point is moot if horses are treated in the absence of these inhibited

stages. Ivermectin does not deliver effective control of these stages [50,51] even at elevated doses [52], however efficacies of the order of 35% to 77% [53] have been reported. Therefore, characterizing such populations as "unexposed and unselected refugia" is both simplistic and incorrect, survivors of the exposure to IVM are able to mature and contribute eggs to the next generation. In contrast, the high efficacy of MOX against all mucosal stages [22,54] leaves few survivors and the contribution of resistance alleles to the next generation is much reduced. Taking into account the current knowledge of rates of selection for resistance in nematodes [55] and the quantitative and qualitative differences in mechanisms of action of resistance, it is strongly recommended that MOX be used strategically as a first line treatment in equine nematode control programmes, and not "saved" for dealing with IVM resistant strains. Although MOX has been shown to control many IVM resistant parasites once resistance to therapeutic levels of IVM has been recognized [56-59] it is likely that the first steps have been taken towards MOX resistance [60-62]. Research continues to elucidate the similarities and differences in IVM and MOX resistance, particularly in relation to P-gps, Multi-drug Resistance Proteins (MRPs) and ABC Transporters [3-5,10-12]. "This new data in a parasitic nematode confirms previous evidence obtained in *C. elegans* that MOX has markedly different and less effect on causing overexpression of both P-gps and MRPs in nematodes compared with IVM. As P-gps and MRPs are involved in the efflux of xenobiotics, their overexpression appears to be a major mechanism of IVM resistance that is not shared, or not shared to the same extent by MOX selection." [63]

Specifically in relation to equines, the presence of at least two P-gp genes has been confirmed in PCR studies conducted in nine different species of cyathostomins [64].

The best uses of MOX will be strategic and pre-emptive use before any ML resistance.

Conclusion

Moxidectin provides safe and effective means of parasite control for horses. As a second-generation ML, it has different chemical, pharmacokinetic and pharmacodynamic characteristics than the first generation MLs, the avermectins, such as higher potency, longer half-life and better diffusion into relevant tissues such as intestinal mucosa. Moxidectin has the longest 'egg reappearance period' after treatment, requiring fewer treatments over a period of time for the same level of control of parasites. This is important, as fewer treatments represent less opportunities for development of nematode resistance, as selection pressure is applied fewer times, compared to other anthelmintic treatments. Through the application

of the known scientific differences unique to MOX we can develop strategic worm control programmes different from those with conventional anthelmintics. An example is the perinatal treatment of mares that can be a viable option to reduce worm transmission to their foals, and to prevent the buildup of infective larvae on foaling pastures. Moxidectin can be used as a conventional anthelmintic in horses but also provides great flexibility and convenience for treatment of important parasitosis in horses, regardless of age or pregnancy status.

Competing interests

The authors acknowledge their affiliation with Fort Dodge Animal Health, the manufacturer of moxidectin, and declare no conflict when writing this review.

Authors' contributions

The two authors contributed equally in the preparation of this review.

Acknowledgements

This article is published as part of *Parasites & Vectors* Volume 2 Supplement 2, 2009. This supplement includes the Proceedings of the "Workshop on equine cyathostomins, the most important parasitic helminth of horses: epidemiology, clinical significance, drug resistance and control" that was held at the University of Teramo, Italy on 20th May, 2009. Additional articles cover other equine nematode parasites, new developments in diagnostic techniques and proposals for more effective sustainable control programmes. The full contents of this supplement are available online at <http://www.parasitesandvectors.com/supplements/2/S2>.

Publication of this supplement has been sponsored by Fort Dodge Animal Health.

References

- Shoop WL, Mrozik H, Fisher MH: **Structure and activity of avermectins and milbemycins in animal health.** *Vet Parasitol* 1995, **59**:139-56
- Rao V, Siddiqui SZ, Prichard RK, Forrester SG: **A dopamine-gated ion channel (HcGGR3*) from *Haemonchus contortus* is expressed in the cervical papillae and is associated with macrocyclic lactone resistance.** *Molecular & Biochemical Parasitology* 2009, **166**:54-61
- Paiement J-P, Leger C, Ribeiro P, Prichard RK: ***Haemonchus contortus*: Effects of glutamate, ivermectin, and moxidectin on inulin uptake activity in unselected and ivermectin-selected adults.** *Experimental Parasitology* 1999, **92**:193-198
- Lespine A, Martin S, Dupuy J, Roulet A, Pineau T, Orłowski S, Alvinerie M: **Interaction of MLs with P-glycoprotein: Structure-affinity relationship.** *Eur J Pharma Sc* 2007, **30**:84-94
- Lespine A, Dupuy J, Orłowski S, Nagy T, Glavinas H, Krajcsi P, Alvinerie M: **Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3).** *Chemico-Biol Interactions* 2006, **159**:169-179
- Mealey, KL: **Therapeutic implications of the MDR-1 gene.** *J Vet Pharmacol Therap*, 2004, **27**:257-64
- Mealey KL, Bentjen S, Waiting D: **Frequency of the mutant MDR1 allele associated with ivermectin sensitivity in a sample population of Collies from the Northwestern United States.** *AJVR* 2002, **63**:479-481
- Griffin J, Fletcher N, Clemence R, Blanchflower S, Brayden DJ: **Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein.** *JVPT*, 2005, **28**:257-265
- Paul A, Tranquilli W, Hutchens D: **Safety of moxidectin in avermectin-sensitive Collies.** *AJVR*, 2000, **61**:482-483

10. Blackhall WJ, Liu HY, Xu M, Prichard RK, Beech RN: **Selection at a P-glycoprotein gene in ivermectin- and moxidectin-selected strains of *Haemonchus contortus***. *Mol Biochem Parasitol*. 1998, **95**:193-201
11. Molento M, Prichard R: **Effects of the multi-drug reversing agents verapamil and CL 347,099 on the efficacy of ivermectin or moxidectin against unselected and drug selected strains of *Haemonchus contortus* in jirds (*Meriones unguiculatus*)**. *Parasitol Res* 1999, **85**: 1007-1011
12. Xu M, Molento M, Blackhall W, Ribeiro P, Beech R, Prichard R: **Ivermectin resistance in nematodes may be caused by alteration of P-glycoprotein homolog**. *Mol Biochem Parasitol* 1998, **91**:327-335
13. Afzal J, Burke A, Batten P, DeLay R, Miller P: **Moxidectin: Metabolic fate and blood pharmacokinetics of ¹⁴C-labeled moxidectin in horses**. *J Agric Food Chem*, 1997, **45**:3627-3633
14. Perez et al: **Comparison of the pharmacokinetics of moxidectin (EQUEST) and ivermectin (EQVALAN) in horses**. *JVPT*, 1999, **22**:174-180
15. Rock D, DeLay R, Gliddon M: **Chemistry, Pharmacology and safety: Moxidectin**. In *Macrocyclic Lactones in Antiparasitic Therapy*. Chapter 14, p 75-96. Edited by J Vercruyse and R Rew
16. Zulalian J, Stout S, daCunha A et al: **Absorption, Tissue Distribution, Metabolism and Excretion of Moxidectin in Cattle**. *Journal of Agricultural and Food Chemistry*, 1997, **42**:381-387
17. Lifschitz A, Imperiale F, Virkel G, Muñoz Cobeñas M, Scherling N, DeLay R, and Lanusse C: **Depletion of Moxidectin Tissue Residues in Sheep**. *J Agric Food Chem*, 2000, **48**:6011-6015
18. Cleale R et al: **A multicenter evaluation of the effectiveness of QUEST Gel (2% moxidectin) against parasites infecting equids**. *Vet Parasit* 2006, **137**:119-129
19. Martin-Downum K, Yazwinski T, Tucker C, Fincher M, Ralph J and Hamilton J: **Cyathostome fecal egg count trends in horses treated with moxidectin, ivermectin or fenbendazole**. *Vet Parasit* 2001, **101**: 75-79
20. Monahan CM, Chapman MR, French DD, Taylor HW and Klei TR: **Dose titration of moxidectin oral gel against gastrointestinal parasites of ponies**. *Vet Parasit* 1995, **59**:241-248
21. Monahan CM; Chapman MR; Taylor HW; French DD; Klei TR: **Comparison of moxidectin oral gel and ivermectin oral paste against a spectrum of internal parasites of ponies with special attention to encysted cyathostome larvae**. *Veterinary Parasit* 1996, **63**:225-235
22. Reinemeyer CR, Farley AW, Clymer BC: **Comparisons of Cyathostome Control and Selection for Benzimidazole Resistance Using Larvicidal Regimens of Moxidectin Gel or Fenbendazole Paste**. *The International Journal of Applied Research* 2003, **1**:1
23. Steinbach T et al: **Small strongyle infection: Consequences of larvicidal treatment of horses with fenbendazole and moxidectin**. *Veterinary Parasit* 2006, **139**:115-131
24. Kivipelto J, Asquith R, Harvey J: **Safety of oral moxidectin in breeding/pregnant mares and their unborn/newborn foals**. In *Proceedings of the AAEP, 41st Annual Meeting*, 1996, Abstract No. 24
25. Mage C et al: **Field efficacy of moxidectin 2% equine gel (EQUEST) against gastrointestinal nematodes in mares with foals**. In *Proceedings of the World Veterinary Congress*, 1999
26. Proudman C, Holdstock N: **Investigation of an outbreak of tapeworm-associated colic in a training yard**. *Equine Veterinary Journal*, 2000, **32**:37-41
27. Faleiros R, Matos J, Alves G, Santos R: ***Anoplocephala magna* related to a case of equine acute abdomen**. *Revista Brasileira de Medicina Veterinaria* 2000, **22**:22-29
28. Barret E, Blair C, Farlam J, Proudman C: **Post dosing colic and diarrhoea in horses with serological evidence of tapeworm**. *Vet Rec* 2005, **156**:252-253
29. Grubbs ST, Amodie D, Rulli D, Wulster-Radcliffe M, Reinemeyer C, Yazwinski T, Tucker C, Hutchens D, Smith L, Patterson D: **Field evaluation of moxidectin/praziquantel oral gel in horses**. *Veterinary therapeutics: research in applied veterinary medicine* 2003, **4**: 249-56
30. Little SE: **Adult tapeworms in horses: Clinical Significance**. *Compend Contin Educ Pract Vet* 1999, **21**:356-360
31. Tolosa Palacios J: **Evaluation of moxidectin and praziquantel, in a combined oral gel formulation, against nematodes and cestodes in horses**. 2001 FDAH Report GASD 08-01.01
32. Herd R, Stinner B, Purrington F: **Dung dispersal and grazing area following treatment of horses with a single dose of ivermectin**. *Vet Parasitol* 1993, **48**:229-240
33. Lumaret J: **Effects of moxidectin/praziquantel equine gel against dung non-target fauna when used at the recommended dose in horses**. 2004 FDAH Report GASD 09-50.00
34. Herd RP, Coles GC: **Slowing the spread of anthelmintic resistant nematodes of horses in the United Kingdom**. *VetRec* 1995, **136**:481-485
35. Herd RP: **Control strategies for ruminant and equine parasites to counter resistance, encystment and ecotoxicity in the USA**. *Vet Parasitol*, 1993, **48**:327-336
36. Boersma JH, Eysker M, Nas JW: **Apparent resistance of *Parascaris equorum* to macrocyclic lactones**. *Vet Rec* 2002, **150**: 279-281
37. Hearn FP, Peregrine AS: **Identification of foals infected with *Parascaris equorum* apparently resistant to ivermectin**. *J Am Vet Med Assoc* 2003, **223**:482-485
38. Craig TM, Diamond PL, Ferwerda NS, Thompson JA: **Evidence of ivermectin resistance by *Parascaris equorum* on a Texas horse farm**. *J Eq Vet Sci* 2007, **27**:67-71
39. Slocombe JOD, de Gannes RVG, Lake MC: **Macrocyclic lactone-resistant *Parascaris equorum* on stud farms in Canada and effectiveness of fenbendazole and pyrantel pamoate**. *Vet Parasit* 2007, **145**(3-4):371-376
40. Schougard H, Nielsen MK: **Apparent ivermectin resistance of *Parascaris equorum* in foals in Denmark**. *Vet Rec* 2007, **160**:439-440
41. Peaty M: ***Parascaris equorum* resistance to moxidectin?** *Vet Rec* 2008, **162**:387
42. Veronese F, Moretta I, Moretti A: **Field effectiveness of pyrantel and failure of *Parascaris equorum* egg count reduction following ivermectin treatment in Italian horse farms**. *Vet Parasitol* 2009, **161**:138-141
43. Molento M, Antunes J, Bentes RN: **Anthelmintic resistance in Brazilian horses**. *Vet Rec* 2008, **162**:384-385
44. Herd R, Gabel A: **Reduced efficacy of anthelmintics in young compared with adult horses**. *Equine Vet Journal*, 1990, **22**:164-169
45. Von Samson-Himmelskjærna G, Fritzen B, Demeler J, Schurmann S, Rohn K, Schneider T, Epe C: **Cases of reduced cyathostomin egg-reappearance period and failure of *Parascaris equorum* egg count reduction following ivermectin treatment as well as survey on pyrantel efficacy on German horse farms**. *Vet Rec* 2007, **144**:74-80
46. Eng JKL, Blackhall WJ, Osei-Atweneboana MY, Bourguinat C, Galazzo D, Beech RN, Unnasch TR, Awadzi K, Lubega GW, Prichard RK: **Ivermectin selection on beta-tubulin: Evidence in *Onchocerca volvulus* and *Haemonchus contortus***. *Molecular & Biochemical Parasitology* 2006, **150**:229-235
47. Taylor S, Kenny J: **Comparison of moxidectin with ivermectin and pyrantel embonate for reduction of faecal egg counts in horses**. *Vet Rec*, 1995, **137**:516-518
48. Vercruyse J, Eysker M, Demeulenaere D, Smets K, Dorny P: **Persistence of the efficacy of moxidectin gel on the establishment of cyathostominae in horses**. *Vet Rec* 1998, **143**:307-309
49. Solari Basano F, Chierichetti N, Genchi C: **Use of moxidectin and ivermectin in cyathostominae yearly control plan. Comparison of efficacy and persistency in naturally infected horses**. *Parassitologia* 1998, **40**:168
50. Eysker M, Boersma J, Kooyman F: **The effect of ivermectin treatment against inhibited early third stage, late third stage and fourth stage larvae and adult stages of cyathostomes in Shetland ponies and spontaneous expulsion of these helminths**. *Vet Parasitol* 1992, **42**:295-302
51. Monahan C, Chapman M, Taylor H, French D, Klei T: **Comparison of moxidectin oral gel and ivermectin paste against a spectrum of internal parasites of ponies with special attention to encysted cyathostome larvae**. *Vet Parasitol*, 1996, **63**:225-235
52. Klei TR, Chapman MR: **Evaluation of ivermectin at an elevated dose against encysted equine cyathostome larvae**. *Vet Parasitol* 1993, **47**:99-106
53. Love S, Duncan JL, Parry JM, Grimshaw WTR: **Efficacy of oral**

- ivermectin paste against mucosal stages of cyathostomes. *Vet Rec* 1995, **136**:18-19**
54. Bello TR, Laningham JET: **A controlled trial evaluation of three oral dosages of moxidectin against equine parasites.** *J Equine Vet Sci* 1994, **14(9)**:483-488
 55. Ranjan S, Wang GT, Hirschlein C, Simkins KL: **Selection for resistance to macrocyclic lactones in *Haemonchus contortus* in sheep.** *Vet Par* 2002, **103**:109-117
 56. Bartley DJ, Jackson F, Sargison N: **Characterization of two triple resistant field isolates of *Teladorsagia* from Scottish lowland sheep farms.** *Vet Par* 2004, **123(3-4)**:189-199
 57. Craig TM, Hatfield TA, Pankavich JA, Wang GT: **Efficacy of moxidectin against an ivermectin-resistant strain of *Haemonchus contortus* in sheep.** *Vet Par*, 1992, **41**:329-333
 58. Kieran, P: **Moxidectin against ivermectin-resistant nematodes – a global view.** *AVJ* 1994, **71(1)**:18-20
 59. Pankavich JA, Berger H, Simkins KL: **Efficacy of moxidectin, nemadectin and ivermectin against an ivermectin-resistant strain of *Haemonchus contortus* in sheep.** *Vet Rec* 1992, **130**:241-243
 60. Molento MB, Wang GT, Prichard RK: **Decreased ivermectin and moxidectin sensitivity in *Haemonchus contortus* selected with moxidectin over 14 generations.** *Vet Par* 1999, **86**:77-81
 61. Pomroy WE, Whelan NC: **Efficacy of moxidectin against an ivermectin-resistant strain of *Ostertagia circumcincta* in young sheep.** *Vet Rec* 1993, **132**:416
 62. Pomroy WE, Whelan N, Alexander AM, West DW, Stafford K, Adlington BA, Calder SM: **Multiple resistance in goat-derived *Ostertagia* and the efficacy of moxidectin and combinations of other anthelmintics.** *NZVJ* 1992, **40**:76-78
 63. Prichard R, Rao V, Siddiqui S, James C, Forrester S: **Studies on the mechanisms of action of moxidectin and ivermectin.** Report on file, 2009.
 64. Drogemuller M, Schnieder T, Von Samson-Himmelstjerna G: **Evidence of P-glycoprotein sequence diversity in cyathostomins.** *Journal of Parasitology* 2004, **90**:998-1003